CTIS2023-504355-28-03进行中（未招募）1 期
NEPA-23-01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-00Helsinn Healthcare S.A.74
招募中
1 期
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2DCTIS2023-508054-25-01anexa AB9
进行中（未招募）
1 期
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2DCTIS2023-508054-25-00anexa AB9
进行中（未招募）
1 期
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.Overweight, ObesityMedDRA version: 20.0Level: PTClassification code: 10033307Term: Overweight Class: 100000004861MedDRA version: 20.0Level: PTClassification code: 10029883Term: Obesity Class: 100000004861CTIS2023-507758-34-00Rose Pharma Inc.12
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55